Tissue fillers derived from decellularized tissues are provided. The tissue fillers can include acellular tissue matrices that have reduced inflammatory responses when implanted in a body. Also provided are methods of making and therapeutic uses for the tissue fillers.

A method of protecting an insertion site permitting passage of a transcutaneous medical device into a patient. The method includes grasping a dressing device, positioning the dressing device over the insertion site, and adhering the dressing device to the patient over the insertion site. The dressing device may include a moisture vapor permeable backing, a polyurethane foam matrix, and an adhesive. The polyurethane foam matrix may be adhered to a first side of the moisture vapor permeable backing, and the adhesive may cover a second side of the moisture vapor permeable backing opposite of the first side. The polyurethane foam matrix can include a polyanhydroglucuronic acid or salt thereof in an amount to achieve a haemostatic effect, and chlorhexidine di-gluconate in an amount of 9% to 16% (w/w) to achieve an antimicrobial effect without adversely affecting wound healing.

The present invention relates to new formulations, particularly useful in the topical treatment of skin and oromucosal wounds. Formulations can be either a solution or a gel form consisting of a Polyhexamethylene biguanide as an antimicrobial agent, purified water and a tri-blockcopolymer, particularly a triblockcopolymer of polyethylene oxide and polypropylene oxide, and more particularly a poloxamer.

A method of reducing surgical site infection (SSI), using a coated medical device having a tissue penetrating surface and an abradable coating on the medical device comprising at least one antimicrobial agent in the coating.

Compositions containing chlorhexidine gluconate solubilized in hydrophobic vehicles are described. Resin systems containing such chlorhexidine gluconate compositions, including adhesives and articles incorporating such resin systems, including medical articles such as drapes are also described.

An absorbent wound dressing comprises a hydrophilic porous substrate and polymer-stabilized silver nanoparticles distributed throughout the porous substrate. The silver nanoparticles have a particle size d.sub.50 in the range of about 45 nm to about 85 nm and the silver nanoparticles are present in the substrate in an amount of about 0.16% to about 1.5% by weight of the total weight of the substrate. The wound dressing produces a 7-day log reduction of 4 or more for bacteria in accordance with the Modified AATCC Test Method 100. The wound dressing is also non-cytotoxic in accordance with ISO 10993-5 standard procedure for medical device cytotoxicity assessment.

Adhesive compositions exhibiting antimicrobial properties, good stability, long shelf lives and enhanced release of antimicrobial agents are described. In certain versions, the compositions also exhibit relatively high fluid handling capacities. The adhesive compositions inhibit microbial growth by more than 2 log after 24 hours contact and particularly more than 3.5 log after 6 hours contact. Also described are various medical articles using such adhesives and related methods.

Provided herein are pre-formulations forming a biocompatible hydrogel polymer comprising at least one nucleophilic compound or monomer unit, at least one electrophilic compound or monomer unit, and optionally a therapeutic agent and/or viscosity enhancer. In some embodiments, the biocompatible hydrogel polymer covers a wound in a mammal and adheres to the surrounding skin tissue. In other embodiments, the hydrogel polymer is delivered into a joint space to treat joint disease or navicular disease.

The subject invention provides materials methods for reducing infections in subjects. The materials methods utilize chlorhexidine, which has been found to be surprisingly non-toxic. The lack of toxicity facilitates the use of chlorhexidine in contexts that were not previously thought to be possible.

Method for the manufacture of a wound care product in which a fabric containing hydroactive constituents, in particular fibres, is processed, whereby the processing of the fabric comprises the application of an antimicrobial means onto the hydroactive constituents.